March 1, 2000

1 Min Read
Enzymatic Therapy

Enzymatic Therapy

GREEN BAY, Wis.--Enzymatic Therapy, partnered with Immodal Pharmaka GmbH ofAustria, has created Saventaro, a cat's claw product scientifically proven andpatented for its positive effects on the natural and acquired immune systems.

Saventaro is the first Uncaria tomentosa product patented that has notetracyclic oxindole alkaloids (TOAs) and is standardized to contain 1.3 percentpentacyclic oxindole alkaloids (POAs). TOAs and POAs are compounds thatdistinguish the two specific chemotypes in Uncaria tomentosa. The two chemotypes,when present together, can inhibit the plant's beneficial effects on theacquired immune system.

Most cat's claw products do not disclose TOA content, and instead generalizethe label claim as containing oxindole alkaloids (OAs). This means that theconsumer may not receive a TOA-free product, which means there is no assurancethe product will offer any health benefits.

Saventaro is extracted solely from the cat's claw root, which contains 200percent more POA compounds than either the leaves or stem hold. For additionalinformation, call (920) 469-4419.

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like